BioNTech SE is 2.8x more valuable than HALOZYME THERAPEUTICS, INC. by market capitalization ($22.90 B vs $8.24 B). Every figure below comes from audited SEC filings and refreshed market data.
| Metric | HALO | BNTX |
|---|---|---|
| Market cap | $8.24 B | $22.90 B |
| US-listed rank | #1065 | #572 |
| Revenue (latest FY) | $1.40B | - |
| Net income (latest FY) | $316.89M | - |
| Net margin | 22.7% | - |
| P/E (trailing FY) | 26.0 | - |
| SEC filings | 1,481 | 548 |
BioNTech SE is 2.8x more valuable than HALOZYME THERAPEUTICS, INC. by market capitalization ($22.90 B vs $8.24 B).
Full pages: HALOZYME THERAPEUTICS, INC. and BioNTech SE, or browse the full rankings.